SCHEMBL312949

SCHEMBL312949

CC(=O)Oc1ccc(O)c(C(C)=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.53
MAOB P27338 2/20 0.53
CYP3A4 P08684 3/20 0.52
KDM4E B2RXH2 4/20 0.51
MAPK1 P28482 2/20 0.50
ACHE P22303 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
LMNA P02545 3/20 0.48
MAPT P10636 4/20 0.46
POLB P06746 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
CA12 O43570 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
CA9 Q16790 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.43
TTR P02766 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31364552 0.87 KDM4E (0.64) CYP3A4KDM4EMAPK1ALDH1A1HPGD
SCHEMBL344841 0.87 KDM4E (0.64) CYP3A4KDM4EMAPK1ALDH1A1HPGD
SCHEMBL7646688 0.85 ALDH1A1 (0.59) MAOAMAOBCYP3A4MAPK1ALDH1A1
SCHEMBL4193452 0.85 CYP3A4 (0.70) MAOAMAOBCYP3A4KDM4EMAPK1
SCHEMBL30976995 0.85 CYP3A4 (0.70) MAOAMAOBCYP3A4KDM4EMAPK1
SCHEMBL8502531 0.84 CA12 (0.61) CYP3A4KDM4EALDH1A1HPGDLMNA
SCHEMBL312754 0.82 ALDH1A1 (0.72) MAOAMAOBCYP3A4KDM4EMAPK1
SCHEMBL20286467 0.82 MAOB (0.54) MAOAMAOBCYP3A4KDM4EMAPK1
SCHEMBL29445806 0.82 ALDH1A1 (0.72) MAOAMAOBCYP3A4KDM4EMAPK1
SCHEMBL15496049 0.82 MAOB (0.48) MAOAMAOBCYP3A4KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed
US-5393776-A Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-02-28 US disclosed
EP-0571928-A1 Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia Bristol-Myers Squibb Company (US) 1993-12-01 EP disclosed
EP-0476493-A1 Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia Bristol-Myers Squibb Company (US) 1992-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 MAOA 251/4885MAOB 385/4885CYP3A4 1730/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 MAOA 251/4885MAOB 385/4885CYP3A4 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.